IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:IRIX
CUSIPN/A
Phone650-940-4700
Debt
Debt-to-Equity RatioN/A
Current Ratio3.77
Quick Ratio2.77
Price-To-Earnings
Trailing P/E Ratio-5.98
Forward P/E Ratio-5.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$41.59 million
Price / Sales1.86
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book2.52
Profitability
EPS (Most Recent Fiscal Year)($1.11)
Net Income$-12,860,000.00
Net Margins-35.95%
Return on Equity-44.78%
Return on Assets-34.72%
Miscellaneous
Employees116
Outstanding Shares11,640,000
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, May, 3rd. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02. The medical equipment provider earned $9.51 million during the quarter, compared to the consensus estimate of $8.80 million. IRIDEX had a negative net margin of 35.95% and a negative return on equity of 44.78%. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What price target have analysts set for IRIX?
1 Wall Street analysts have issued twelve-month price objectives for IRIDEX's shares. Their forecasts range from $13.00 to $13.00. On average, they expect IRIDEX's share price to reach $13.00 in the next twelve months. View Analyst Ratings for IRIDEX.
Who are some of IRIDEX's key competitors?
Some companies that are related to IRIDEX include Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), BioLife Solutions (BLFS), Second Sight Medical Products (EYES), Zynex Inc. common stock (ZYXI), Edap Tms (EDAP), Viveve Medical (VIVE), Semler Scientific (SMLR), BioSig Technologies (BSGM), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Digirad (DRAD) and Aradigm (ARDM).
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman, Chief Exec. Officer and Pres (Age 69)
- Mr. Atabak Mokari, Chief Financial Officer and VP of Corp. Devel. (Age 41)
- Dr. George R. Marcellino Ph.D., VP of Clinical Affairs & Director (Age 69)
- Mr. Timothy D. Buckley, VP of Global Marketing & Bus. Devel. (Age 43)
- Ms. Stacie Rodgers, VP of HR
Has IRIDEX been receiving favorable news coverage?
News articles about IRIX stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. IRIDEX earned a news sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 45.67 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are IRIDEX's major shareholders?
IRIDEX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (3.33%), Isthmus Partners LLC (0.76%), Millennium Management LLC (0.40%) and Blair William & Co. IL (0.37%). Company insiders that own IRIDEX stock include George R Marcellino, Romeo R Dizon, Ruediger Naumann-Etienne and William M Moore. View Institutional Ownership Trends for IRIDEX.
Which major investors are selling IRIDEX stock?
Which major investors are buying IRIDEX stock?
IRIX stock was bought by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Blair William & Co. IL and Isthmus Partners LLC. View Insider Buying and Selling for IRIDEX.
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $6.64.
How big of a company is IRIDEX?
IRIDEX has a market capitalization of $77.27 million and generates $41.59 million in revenue each year. The medical equipment provider earns $-12,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. IRIDEX employs 116 workers across the globe.
How can I contact IRIDEX?
IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]
MarketBeat Community Rating for IRIDEX (IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
